Effect of everolimus on multifocal micronodular pneumocyte hyperplasia in tuberous sclerosis complex.
Fiche du document
2020
- doi: 10.1016/j.rmcr.2020.101310
- issn: 2213-0071
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.rmcr.2020.101310
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/33312857
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/2213-0071
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_D07C5F1D118C8
info:eu-repo/semantics/openAccess , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
Sujets proches
Epiloia Sclerosis, Tuberous Bourneville's diseaseCiter ce document
C. Daccord et al., « Effect of everolimus on multifocal micronodular pneumocyte hyperplasia in tuberous sclerosis complex. », Serveur académique Lausannois, ID : 10.1016/j.rmcr.2020.101310
Métriques
Partage / Export
Résumé
Multifocal micronodular pneumocyte hyperplasia (MMPH) is a benign proliferation of alveolar type II cells presenting as multiple pulmonary nodules at chest imaging, which is frequently seen in patients with tuberous sclerosis complex (TSC). We report a case of a woman with TSC and MMPH who received everolimus, a mechanistic target of rapamycin (mTOR) inhibitor, for the treatment of a subependymal giant cell astrocytoma (SEGA). After 3 months of therapy, a remarkable decrease in density of all pulmonary MMPH lesions was observed, without any change in size. This shows that everolimus is active on MMPH similarly to its effects on SEGA, renal angiomyolipomas, and pulmonary lymphangioleiomyomatosis in TSC, and suggests that the dysregulated activation of mTOR which characterizes TSC also plays a role in the pathogenesis of MMPH.